Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03493698
Other study ID # SBP-9200-HBV-202
Secondary ID 2018-000607-16
Status Completed
Phase Phase 1
First received
Last updated
Start date May 7, 2018
Est. completion date August 27, 2018

Study information

Verified date September 2020
Source Spring Bank Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, open-label, fixed sequence study to investigate the effect of multiple oral dosing of Inarigivir Soproxil and a single oral dose of Midazolam in Healthy Subjects


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date August 27, 2018
Est. primary completion date August 27, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

1. Gender : male or female

2. Age : 18-55 years, inclusive, at screening

3. Body mass index (BMI) : 18.0-30.0 kg/m2, inclusive, at screening

4. Status : healthy subjects

5. At screening, females must be non-pregnant and non-lactating, or of non-childbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year post-menopausal [amenorrhoea duration of 12 consecutive months]); non-pregnancy will be confirmed for all females by a serum pregnancy test conducted at screening, and a urine pregnancy test at each admission and at follow-up

6. Female subjects of childbearing potential, with a fertile male sexual partner, must agree to use adequate contraception from screening until 90 days after the follow-up visit. Adequate contraception is defined as using a non-hormonal intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom; please note that hormonal contraceptives are not allowed. Also, total abstinence, in accordance with the lifestyle of the subject, is acceptable

7. Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner) is defined as using hormonal contraceptives or an intrauterine device, combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the subject is acceptable

8. All prescribed medication, including hormonal contraceptives for female subjects, must have been stopped at least 30 days prior to admission to the clinical research center

9. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John's Wort) must have been stopped at least 14 days prior to admission to the clinical research center. An exception is made for paracetamol, which is allowed up to admission to the clinical research center

10. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks) and grapefruit (juice) from 72 hours prior to admission to the clinical research center

11. Good physical and mental health on the basis of medical history, physical examination, clinical laboratory, electrocardiogram (ECG) and vital signs, as judged by the PI

12. Willing and able to sign the ICF

Exclusion Criteria:

1. Employee of PRA or the Sponsor

2. History of relevant drug and/or food allergies

3. Using tobacco products within 60 days prior to the first drug administration

4. History of alcohol abuse or drug addiction (including soft drugs like cannabis products)

5. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol) at screening and admission to the clinical research center

6. Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

7. Positive screen for hepatitis B surface antigen (HBsAg), anti-HCV antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies

8. Participation in a drug study within 60 days prior to the first drug administration in the current study. Participation in more than 4 other drug studies in the 12 months prior to the first drug administration in the current study

9. Donation or loss of more than 100 mL of blood within 60 days prior to the first drug administration. Donation or loss of more than 1.5 liters of blood (for male subjects) / more than 1.0 liters of blood (for female subjects) in the 10 months prior to the first drug administration in the current study

10. Significant and/or acute illness within 5 days prior to the first drug administration that may impact safety assessments, in the opinion of the PI

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Midazolam
Midazolam
Inarigivir
Inarigivir

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (2)

Lead Sponsor Collaborator
Spring Bank Pharmaceuticals, Inc. PRA Health Sciences

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (Cmax) Comparison of Cmax for midazolam between Treatments A and D. Day 1 Treatment A and Day 19 Treatment D, respectively
Primary Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-t) Comparison of AUC0-t for midazolam between Treatments A and D. Day 1 Treatment A and Day 19 Treatment D, respectively
Primary Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-inf ) Comparison of AUC0-inf for midazolam between Treatments A and D. Day 1 Treatment A and Day 19 Treatment D, respectively
Secondary Number of Participants With Clinical Relevant Clinical Laboratory, Vital Signs, 12-lead ECG, or Physical Examination Safety and tolerability were measured via clinical laboratory evaluations, vital signs, 12-lead ECG, or physical examination Day -1 to Day 20 and Follow-up (5-9 days post-treatment)
Secondary PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (AUC) A summary of the main plasma PK parameters for inarigivir, Rp-SB 9000, Sp-SB 9000, and Rp-SB 9000 and Sp-SB 9000 combined after a single oral dose of 400 mg inarigivir on Day 3 (Treatment B) and after the last of 14 consecutive daily oral doses of 400 mg inarigivir from Day 6 to 19 (Treatment D) Day 3 and Day 6 to 19
Secondary PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (Cmax) A summary of the main plasma PK parameters for inarigivir, Rp-SB 9000, Sp-SB 9000, and Rp-SB 9000 and Sp-SB 9000 combined after a single oral dose of 400 mg inarigivir on Day 3 (Treatment B) and after the last of 14 consecutive daily oral doses of 400 mg inarigivir from Day 6 to 19 (Treatment D) Day 3 and Day 6 to 19
See also
  Status Clinical Trial Phase
Completed NCT03789032 - Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat Phase 1
Completed NCT03706222 - Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan
Completed NCT02191358 - YouScript IMPACT Registry N/A
Completed NCT02485028 - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg Phase 1
Completed NCT01896557 - Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Phase 4
Completed NCT03011463 - Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1 Phase 1
Completed NCT02485041 - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg Phase 1
Completed NCT01477411 - A Drug-Drug Interaction Study of Digoxin and PA21 Phase 1
Completed NCT01477424 - A Drug-Drug Interaction Study of Warfarin and PA21 Phase 1
Completed NCT05558150 - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac Phase 1
Completed NCT03126578 - Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam Phase 1
Completed NCT01369186 - Drug Drug Interactions of Aspirin and P2Y12-inhibitors Phase 4
Completed NCT02378220 - Pharmacogenetic Testing Among Home Health Patients N/A
Completed NCT01324752 - A Drug-Drug Interaction Study of Losartan and PA21 Phase 1
Completed NCT02500667 - A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects Phase 1
Completed NCT03801733 - Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin Phase 1
Completed NCT03801759 - Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide Phase 1
Completed NCT03801746 - Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin Phase 1
Completed NCT01736371 - Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion. N/A
Completed NCT05237297 - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole Phase 1